Company Filing History:
Years Active: 2019
Title: Jangbeen Kyung: Innovator in Pharmaceutical Compounds
Introduction
Jangbeen Kyung is a notable inventor based in Gyeonggi-do, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target specific diseases. His work focuses on innovative solutions that can lead to effective treatments for various health conditions.
Latest Patents
Jangbeen Kyung holds a patent for "1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same." This invention relates to novel compounds that exhibit histone deacetylase 6 (HDAC6) inhibitory activity. The compounds, including their stereoisomers and pharmaceutically acceptable salts, are designed for therapeutic use. They are effective in preventing or treating HDAC6-mediated diseases, which encompass a wide range of conditions such as infectious diseases, neoplasms, and neurological disorders.
Career Highlights
Jangbeen Kyung is associated with Chong Kun Dang Pharmaceutical Corporation, where he continues to advance his research and development efforts. His work has the potential to impact the pharmaceutical industry significantly, providing new avenues for treatment and improving patient outcomes.
Collaborations
Jangbeen collaborates with esteemed colleagues, including Jaekwang Lee and Younghue Han. Their combined expertise enhances the research and development process, fostering innovation in the pharmaceutical sector.
Conclusion
Jangbeen Kyung's contributions to pharmaceutical innovations highlight the importance of research in developing effective treatments for complex diseases. His work exemplifies the potential of novel compounds in advancing medical science and improving health outcomes.